BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 22, 2010
 |  BioCentury  |  Product Development

Triple Threat in IPF

Boehringer hopes its triple kinase inhibitor can improve outcomes in IPF

As the understanding of idiopathic pulmonary fibrosis has grown, it's becoming clearer that a variety of growth factors and proteins contribute to development of the disease. Boehringer Ingelheim GmbH believes data from a Phase II trial show that targeting multiple growth factors with its triple kinase inhibitor, BIBF 1120, can lead to better clinical outcomes.

The question now is how to move it forward.

Given FDA's skepticism about forced vital capacity (FVC) as a clinically relevant endpoint, the company says it may need to consider mortality as a primary endpoint if it decides to move BIBF 1120 into Phase III testing.

The predominant forms of disease-causing cells in IPF, fibroblasts and myofibroblasts, are activated by growth factors following inflammatory damage to the lungs. These cells can proliferate and lead to the synthesis of extracellular matrix and collagen, the main components in...

Read the full 700 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >